system: You are a contract-analysis assistant performing a span-extraction task. You are given an excerpt from a commercial contract and the name of a clause type to locate within it.

Return the exact text of the requested clause, copied verbatim from the excerpt — identical wording and punctuation, with no paraphrasing, summarising, explanation, or added commentary.

The excerpt is one window of a much longer contract and often will not contain the requested clause. If the requested clause does not appear in this excerpt, respond with exactly: Not found.

Output only the extracted clause text, or the exact string `Not found.` — nothing else.

user: Contract excerpt:
"""
Exhibit 10.2 STRATEGIC ALLIANCE AGREEMENT dated as of August 26, 2015 among Sucampo Pharmaceuticals, Inc., Sucampo Pharma, LLC. and R-Tech Ueno, Ltd. TABLE OF CONTENTS ARTICLE I DEFINITIONS AND INTERPRETATION Section 1.01 Definitions 2 Section 1.02 Interpretation 8 ARTICLE II TRANSACTION Section 2.01 Strategic Alliance 8 Section 2.02 Obligations of Acquiror 9 Section 2.03 Obligations of the Company 11 ARTICLE III REPRESENTATIONS AND WARRANTIES Section 3.01 Representations and Warranties of the Company 11 Section 3.02 Representations and Warranties of Acquiror 12 ARTICLE IV COVENANTS OF THE PARTIES Section 4.01 The Company's Obligation 12 Section 4.02 Consummation of the Squeeze-out 15 Section 4.03 Applications and Consents; Governmental Communications and Filings 15 Section 4.04 Further Assurance 15 Section 4.05 Access 15 Section 4.06 Notifications 16 Section 4.07 Confidentiality 16 Section 4.08 Public Announcement 17 Section 4.09 No Lender Liability 17 Section 4.10 Employees of Company 17 Section 4.11 Development Programs and Clinical Trials 18 ARTICLE V INDEMNIFICATION Section 5.01 Indemnification by the Company 18 Section 5.02 Indemnification by Acquiror 18 Section 5.03 Indemnification Procedure 18 Section 5.04 Limitations 18 i ARTICLE VI TERMINATION Section 6.01 Termination 19 Section 6.02 Notice of Termination 19 Section 6.03 Effect of Termination 19 ARTICLE VII GUARANTEE Section 7.01 Guarantee 19 ARTICLE VIII MISCELLANEOUS Section 8.01 Governing Law 19 Section 8.02 Jurisdiction 19 Section 8.03 Cost and Expenses 20 Section 8.04 Assignment 20 Section 8.05 Amendments and Waivers 20 Section 8.06 Severability 20 Section 8.07 Counterparts 21 Section 8.08 Entire Agreement 21 Section 8.09 Notices 21 Section 8.10 Language 22 Section 8.11 Disclosure Schedules 22 Section 8.12 Fraud 22 Section 8.13 Third-party Beneficiaries 23 ii STRATEGIC ALLIANCE AGREEMENT This STRATEGIC ALLIANCE AGREEMENT is made and entered into as of August 26, 2015 (this "Agreement"), by and among R-Tech Ueno, Ltd., a corporation organized under Japanese law (the "Company"), Sucampo Pharma, LLC., a corporation organized under Japanese law ("Acquiror"), and Sucampo Pharmaceuticals, Inc., a corporation organized under Delaware law ("SPI," and, together with the Company and Acquiror, collectively, the "Parties"). RECITALS WHEREAS, the Acquiror is a wholly-owned subsidiary of SPI, which operates a biopharmaceutical business focused on the research and development of proprietary drugs; WHEREAS, the Company operates a drug discovery and manufacturing business; WHEREAS, Acquiror and the Company share the objective of creating a combined biopharmaceutical company that can drive considerable growth in global markets, including Japan; WHEREAS, the Company has currently in issuance and outstanding 19,312,300 shares of common stock (the "Common Stock") and stock options representing an additional 328,600 shares of Common Stock (the "Stock Options", and together with the issued and outstanding Common Stock, the "Target Securities"); WHEREAS, pursuant to the terms and subject to the conditions set forth herein, Acquiror has agreed to commence a tender offer bid (such tender offer bid, including any amendments or extensions thereto made in accordance with the terms of this Agreement and applicable Law, including Articles 27-2 through 27-22 of the FIEL, the "Offer") to acquire for cash (i) all of the issued and outstanding shares of Common Stock at a price per share of JPY1,900 (the "Share Offer Price") and (ii) all of the outstanding Stock Options at the price prescribed in this Agreement; WHEREAS, the Company has agreed, on the terms and subject to the conditions set forth herein, to support the Offer and recommend the holders of Target Securities to tender their shares of Common Stock and Stock Options to the Offer and publicly announce such statement; WHEREAS, Jefferies Finance LLC ("Jefferies") has entered into a financing commitment letter, dated as of August 26, 2015, between SPI and Jefferies (the "Financing Commitment"), pursuant to which Jefferies has committed to provide debt financing for the Offer in the aggregate amount and on the terms and conditions set forth therein (the "Financing"); 1 NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements herein contained, and intending to be legally bound hereby, the Parties hereby agree as follows: ARTICLE I DEFINITIONS AND INTERPRETATION Section 1.01 Definitions. As used in this Agreement, the following terms have the respective meanings set forth below: "Acquiror" shall have the meaning set forth in the preamble hereto. "Action" shall mean any claim, action, suit, arbitration, mediation, proceeding or investigation, whether civil, criminal or administrative, by or before any Governmental Authority or arbitral body. "Affiliate" shall mean, (i) with respect to a particular individual, (A) the individual's spouse and any parent, child, sibling, grandparent, grandchild, aunt, uncle, niece, nephew of the individual or the individual's spouse, (B) any Person
"""

Extract the exact clause related to "License Grant" from the excerpt above.